Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA's Center for Biologics Evaluation and Research slapped CSL Biotherapies with a warning letter June 15 for significant objectionable conditions related to current good manufacturing practices at its Victoria, Australia, manufacturing plant